Role of the combination spironolactone– norgestimate–estrogen in hirsute women with polycystic ovary syndrome

Journal of Reproductive Medicine

Volumn 59, Issue 5, 2014, Pages 455-463

  Hagag, Philippe ^a,b   Steinschneider, Miriam ^a,b   Weiss, Mordechai ^a,b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Androgen excess; Blood count; Ethinyl estradiol; Hirsutism; Hyperandrogenism; Lipid profile; Norgestimate; PCOS; Polycystic ovary syndrome; Spironolactone

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; CYPROTERONE; ESTRADIOL; ETHINYLESTRADIOL; FIBRINOGEN; FOLLITROPIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; NORGESTIMATE; POTASSIUM; SPIRONOLACTONE; TESTOSTERONE; TRIACYLGLYCEROL; ESTROGEN; NORGESTREL;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; OPEN STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; YOUNG ADULT; ANALOGS AND DERIVATIVES; BLOOD; DRUG COMBINATION; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME;

ADULT; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HIRSUTISM; HUMANS; NORGESTREL; POLYCYSTIC OVARY SYNDROME; SPIRONOLACTONE; TESTOSTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921959261     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Azziz R: Adrenal androgen excess in polycystic ovary syndrome. In Polycystic Ovary Syndrome. Edited by RJ Chang, JJ Heindel, A Dunaif. New York, Marcel Dekker Inc., 2002, pp 77-87
2. Orio F, Palomba S, Colao A: Cardiovascular risk in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S20-S21
3. Moghetti P, Tosi F, Tosti A, et al: Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94
4. Swiglo BA, Cosma M, Flynn DN, et al: Clinical review: Antiandrogens for the treatment of hirsutism: A systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008;93:1153-1160
5. Gökmen O, Senöz S, Gülekli B, et al: Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol 1996;10:249-255
6. Grunwald K, Rabe T, Schlereth G, et al: Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization. Geburtshilfe Frauenheilkd 1994;54:634-645
7. Archer DF, Lasa IL: Tailoring combination oral contraceptives to the individual woman. Womens Health (Larchmt) 2011;20:879-891
8. Henzl MR: Norgestimate: From the laboratory to three clinical indications. J Reprod Med 2001;46:647-661
9. Langer RD, Friedman AJ: Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids. J Reprod Med 2006;51:610-616
10. Lidegaard O/, Lo/kkegaard E, Jensen A, et al: Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-2266
11. Markantes G, Saltamavros AD, Vervita V, et al: Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 mcg ethinyl estradiol and 2 mg cyproterone acetate. Gynecol Endocrinol 2011;27:971-977
12. Newton JN, Mallon E, Klassen A, et al: The effectiveness of acne treatment: An assessment by patients of the outcome of therapy. Br J Dermatology 1997;137:563-567
13. Guzelmeric K, Sekel N, Unal O, et al: High serum prostatespecific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol 2004; 19:190-195
14. O'Brien RC, Cooper ME, Murray RM, et al: Comparison of sequential cyproterone acetate/estrogen versus spironolactone/ oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab 1991;72:1008-1013
15. Erenus M, Yücelten D, Gürbüz O, et al: Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril 1996;66:216-219
16. Shelepova T, Nafziger AN, Victory J, et al: Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005;45:1413-1421
17. Lindenmaier H, Becker M, Haefeli WE, et al: Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos 2005;33:1576-1579
18. White T, Jain JK, Stanczyk FZ: Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005;192:2055-2059
19. Couzinet B, Le Strat N, Brailly S, et al: Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J Clin Endocrinol Metab 1986;63:1031-1035
20. Koninckx PR, Lauweryns JM, Cornillie FJ: Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation. Maturitas 1993;16:97-110
21. Regidor PA, Speer K, Regidor M, et al: Long-term sideeffects following cyproterone acetate containing therapy in gynecology. Zentralb Gynakol 2000;122:268-273
22. van Wayjen RG, van den Ende A: Experience in the longterm treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: Efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995;103:241-251
23. Barth JH, Cherry CA, Wojnarowska F, et al: Cyproterone acetate for severe hirsutism: Results of a double-blind doseranging study. Clin Endocrinol (Oxf) 1991;35:5-10
24. Falsetti L, Gambera A, Tisi G: Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 2001;16:36-42
25. Tan JK: New developments in hormonal therapy for acne. Skin Therapy Lett 2007;12:1-3
26. Mulders AG, ten-Kate Booij MT, Pal R, et al: Influence of oral contraceptive pills on phenotype expression in women with polycystic ovary syndrome. Reprod Biomed Online 2005;11: 690-696
27. Rosner W, Auchus RJ, Azziz R, et al: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab 2007;92:405-413
28. Honour JW, Tsilchorozidou T, Conway GS, et al: Spironolactone interference in the immunoassay of androstenedione. Ann Clin Biochem 2010;47:564-566
29. Ibanez L, Jaramillo AM, Ferrer A, et al: High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: Normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 2005;20:2457-2462
30. Atiomo WU, Bates SA, Condon JE, et al: The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69:236-241
31. White T, Ozel B, Jain JK, et al: Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293-296
32. Kluft C: Effects on haemostasis variables by second and third generation combined oral contraceptives: A review of directly comparative studies. Curr Med Chem 2000;7:585-591
33. Ernst E, Schmölzl C, Matrai A, et al: Hemorheological effects of oral contraceptives. Contraception 1989;40:571-580
34. Glintborg D, Andersen M, Richelsen B, et al: Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf) 2009;71:652-658
35. Kleynhans L, Du Plessis N, Black GF, et al: Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users. Plos One 2011;6:e24639
36. Thomas T, Rhodin J, Clark L, et al: Progestins initiate adverse events of menopausal estrogen therapy. Climacteric 2003;6: 293-301
37. Klinger G, Gräser T, Mellinger U, et al: A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system. Gynecol Endocrinol 2000;14:15-24
38. Ahokas RA, Warrington KJ, Gerling IC, et al: Aldosteronism and peripheral blood mononuclear cell activation: A neuroendocrine-immune interface. Circ Res 2003;93:e124- e135
39. Godfrey V, Farquharson CA, Macdonald JE, et al: Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol 2007;117:282-284
40. Bouman A, Schipper M, Heineman MJ, et al: 17betaestradiol and progesterone do not influence the production of cytokines from lipopolysaccharide-stimulated monocytes in humans. Fertil Steril 2004;82(Suppl 3):1212-1219
41. Waterhouse DF, Cahill RA, Sheehan F, et al: Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population. Vasc Health Risk Manag 2008;4:177-187
42. Johnsen SH, Fosse E, Joakimsen O, et al: Monocyte count is a predictor of novel plaque formation: A 7-year follow-up study of 2610 persons without carotid plaque at baseline: The Tromso/ Study. Stroke 2005;36:715-719
43. Nasir K, Guallar E, Navas-Acien A, et al: Relationship of monocyte count and peripheral arterial disease: Results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Thromb Vasc Biol 2005;25:1966-1971
44. Lippi G, Filippozzi L, Salvagno GL, et al: Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009;133:1441-1443
45. Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al: Mean platelet volume: A link between thrombosis and inflammation? Curr Pharm Des 2011;17:47-58
46. Melis GB, Fruzzetti F, Nicoletti I, et al: A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991;43:23-31
47. Scharnagl H, Petersen G, Nauck M, et al: Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 2004;69:105-113
48. Falsetti L, Pasinetti E: Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 1995;74:56-60
49. Nakhjavani M, Hamidi S, Esteghamati A, et al: Short term effects of spironolactone on blood lipid profile: A 3-month study on a cohort of young women with hirsutism. Br J Clin Pharmacol 2009;68:634-637